A federal district court in Pennsylvania denied Janssen Biotech Inc.'s motion to dismiss Xoma Royalty Corp.'s action related to licensing agreements for patented technology and research tools for bacterial cell expression instrumental to the discovery and isolation of the active ingredient in Tremfya®. The court said that Xoma stated claims for breach of contract and unjust enrichment, and had standing to enforce provisions of the agreement.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.